(Q52617680)

4 May 2018

title

Myo-inositol in the treatment of premenstrual dysphoric disorder. (English)

1 reference

4 May 2018

author name string

Carlomagno Gianfranco

1

1 reference

4 May 2018

Unfer Vittorio

2

1 reference

4 May 2018

Buffo Silvia

3

1 reference

4 May 2018

D'Ambrosio Francesco

4

1 reference

4 May 2018

publication date

1 October 2011

1 reference

4 May 2018

published in

Human Psychopharmacology

1 reference

4 May 2018

volume

26

1 reference

4 May 2018

issue

7

1 reference

4 May 2018

page(s)

526-530

1 reference

4 May 2018

Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder.

cites work

1 reference

Estimating direct and indirect costs of premenstrual syndrome

21 January 2018

1 reference

Premenstrual dysphoric disorder: is there an economic burden of illness?

21 January 2018

1 reference

Inositol as an add-on treatment for bipolar depression.

21 January 2018

1 reference

Update on research and treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors

21 January 2018

1 reference

Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria

21 January 2018

1 reference

Inositol treatment of post-traumatic stress disorder.

21 January 2018

1 reference

Double-blind, controlled trial of inositol treatment of depression

21 January 2018

1 reference

Serotonin transporter gene polymorphisms and platelet [3H] paroxetine binding in premenstrual dysphoria.

21 January 2018

1 reference

Myo-inositol has no beneficial effect on premenstrual dysphoric disorder

21 January 2018

1 reference

Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome

21 January 2018

1 reference

A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria.

21 January 2018

1 reference

Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.

21 January 2018

1 reference

Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls.

21 January 2018

1 reference

Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers

21 January 2018

1 reference

Burden of premenstrual dysphoric disorder on health-related quality of life.

21 January 2018

1 reference

The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD).

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Pindolol excites dopaminergic and adrenergic neurons, and inhibits serotonergic neurons, by activation of 5-HT1A receptors

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Altered 5-HT(2A) binding sites and second messenger inositol trisphosphate (IP(3)) levels in hippocampus but not in frontal cortex from depressed suicide victims

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HUP.1241

1 reference

4 May 2018

PubMed ID

22031267

1 reference

4 May 2018